Journal article

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study

Christine Y Chen, Tien Y Wong, Wilson J Heriot

AMERICAN JOURNAL OF OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2007

Abstract

PURPOSE: To report the short-term study of intravitreal bevacizumab (Avastin) in the treatment of neovascular age-related macular degeneration (AMD). DESIGN: Interventional, consecutive, prospective case series. METHODS: One hundred and two eyes of 102 patients with neovascular AMD received monthly intravitreal bevacizumab (Avastin) (1.25 mg) until resolution of macular edema, subretinal fluid, and/or pigment epithelial detachment. Outcome measures included visual acuity (VA) and central retinal thickness as defined from optical coherence tomography (OCT). RESULTS: Mean VA was 20/80 and OCT central retinal thickness was 251.0 +/- 74.6 microm before injection and improved to 20/63 and 214.9 +..

View full abstract